抗癌药降价,正在上演一出大戏

2018-08-15 山东风轻 赛柏蓝

抗癌药降价,“活脱脱”正在上演的“一出好戏”!

最近有两则涉及抗癌药的信息比较耐人寻味。

第一则,8月9日,陕西省卫计委下发了《关于召开省际联盟进口抗癌药品专项采购工作研讨会的通知》,包括陕西、内蒙古、宁夏等12个省(区)齐聚研讨《省际联盟进口抗癌药品专项采购议价方案》和《省际联盟进口抗癌药品专项采购工作方案》;第二则,继部分省级抗癌仿制药医保支付标准调整后,国家医保局办公室、人社部办公厅、卫计委办公厅联合下发文件,对国家谈判抗癌药品医保支付标准和采购价格也进行了调整。

抗癌药降价,“活脱脱”正在上演的“一出好戏”!

“好戏”精彩有三:

草灰蛇线,国家示范降价。

今年5月1日起,进口抗癌药品关税降至零,同时原来16%的增值税可选择按3%简易纳税征收。对抗癌药减免税政策具体内容包括:“进口抗癌药零关税、部分进口抗癌药按3%征收进口环节增值税、企业可选择按照简易办法依照3%缴纳流通环节的增值税”三个方面。

但三个月过去,税降了,部分省也采取了许多措施降价,但许多医疗机构却没有感到价格下降,部分患者也没感受到调价的实惠,原因一方面是价格传导到终端需要一段时间,另一方面则是有些省已经“动”了,但还是有少数省份“动作”不明显。

于是,国家示范性的对相关谈判药品进行降价,既是表明一种降价的坚决态度,也是无声地督促相关区域抓紧落实降价措施。

珠胎明结,区域联盟联合降价。

区域联盟进行联合降价,本不是什么新鲜事物,前有三明联盟,后有四省一市,去年至今,广东湖北联盟、重庆甘肃联盟又抢足了眼球,但海枯石烂的“海誓联盟”在“抗癌药”这个敏感面前,却显得有些踌躇顾虑——国家医保局刚刚组建,各地医保局即将陆续成立,“观望观望”、“再稍等等”的氛围是有的。

用某省级药品集采领导的原话讲,国家医保局助推区域交易要有四要素考虑:要有跨区合作基础、要有战略伙伴资源、要有组织实施能力、要有主动配合意愿!

此话一点不虚,以此次陕西牵头组织相关会议来看,12个地方大多数是西部省份,各省病种和用药结构具有一定相似性,分析人士告诉笔者,“建立同病种、同品种的跨区域采购联盟,使区域性抗癌药采购范围更为精准、采购规模更为具体、同时也为企业提供了精准的目标市场,降低企业市场营销成本,更有利于促进降价”。

敲山震虎,企业主动降价。在国家降税、地方要求企业申报的背景下,有的聪明企业不等相关省份发布通知,第一时间主动申请降价。提前降价,一方面可以占领相对优势的政策正确高地,体现社会责任感,另一方面主动降价,也会为下一步省级、省际的招标采购降价做好铺垫,毕竟,人们总是同情“弱者”的。

对于抗癌药来说,降价是铁定的,以价换量是可能的,没有更低只有最低是符合政策精神的。

根据电影的推进方式,往往影片最后会放一个彩蛋,那么,抗癌药降价这部好戏的彩蛋是什么呢?

那就是刚刚公布的《2018年度江西省抗癌药专项集中采购实施方案(征求意见稿)》,在这份意见稿中,对采取双信封制公开招标采购入围商务标的产品,同一目录分组的按照经济技术标评分,划分为两个竞价组(≥75分为第1竞价组,<75分为第2竞价组),此次经济技术标份量最重的40分一栏中,江西直接借鉴近两年杀价的流行方式并略有创新,赫然将“化合物专利药品、原研制药品、仿制药参比制剂、通过仿制药一致性评价药品”四项并作一列,同时规定,已享受税收减免政策,无特殊原因拒不降价的,取消采购资格。江西已经给试图不降价的药品提前敲响了警钟。

无论是国家、省际、省级开始对抗癌仿制药品进行降价,最终的靶向,其实还是瞄着原研药(原研药内心再受一万点苦涩爆击),最终达到一石四鸟的效果(仿制药提前调价、原研药被迫主动或被动降价、消费者获益社会各界满意、医保资金得到有效控制)。

抗癌药降价只是一个阶段性的过程,通过抗癌药降价总结提炼下一步药品采购的经验,这才是真正的大戏。所以,从这个角度来讲,这一出好戏还没有结束,因为,“好戏在后头!”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=367757, encodeId=56a236e7573e, content=了解了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/02/328c4971762e29538e4842286ddd170b.jpg, createdBy=36742075189, createdName=首丘, createdTime=Sat Jun 15 00:13:05 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314793, encodeId=15ae1314e936c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425039, encodeId=65bc142503947, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338832, encodeId=a247338832fa, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Aug 15 22:02:21 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338809, encodeId=1f3a3388095e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Wed Aug 15 19:34:48 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2019-06-15 首丘

    了解了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=367757, encodeId=56a236e7573e, content=了解了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/02/328c4971762e29538e4842286ddd170b.jpg, createdBy=36742075189, createdName=首丘, createdTime=Sat Jun 15 00:13:05 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314793, encodeId=15ae1314e936c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425039, encodeId=65bc142503947, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338832, encodeId=a247338832fa, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Aug 15 22:02:21 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338809, encodeId=1f3a3388095e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Wed Aug 15 19:34:48 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-17 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=367757, encodeId=56a236e7573e, content=了解了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/02/328c4971762e29538e4842286ddd170b.jpg, createdBy=36742075189, createdName=首丘, createdTime=Sat Jun 15 00:13:05 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314793, encodeId=15ae1314e936c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425039, encodeId=65bc142503947, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338832, encodeId=a247338832fa, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Aug 15 22:02:21 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338809, encodeId=1f3a3388095e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Wed Aug 15 19:34:48 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-17 30397605
  4. [GetPortalCommentsPageByObjectIdResponse(id=367757, encodeId=56a236e7573e, content=了解了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/02/328c4971762e29538e4842286ddd170b.jpg, createdBy=36742075189, createdName=首丘, createdTime=Sat Jun 15 00:13:05 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314793, encodeId=15ae1314e936c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425039, encodeId=65bc142503947, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338832, encodeId=a247338832fa, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Aug 15 22:02:21 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338809, encodeId=1f3a3388095e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Wed Aug 15 19:34:48 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-15 天地飞扬

    了解一下,谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=367757, encodeId=56a236e7573e, content=了解了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/02/328c4971762e29538e4842286ddd170b.jpg, createdBy=36742075189, createdName=首丘, createdTime=Sat Jun 15 00:13:05 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314793, encodeId=15ae1314e936c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425039, encodeId=65bc142503947, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Aug 17 09:19:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338832, encodeId=a247338832fa, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Aug 15 22:02:21 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338809, encodeId=1f3a3388095e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Wed Aug 15 19:34:48 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-15 小小小麦兜

    学习了

    0

相关资讯

抗癌药价格到底能降多少?降幅或在2%-6%

今年5月1日至今,中国实施抗癌药等药品“零关税”已超过3个月。“救命药”买不起的问题是否得到缓解,备受外界关注。抗癌药实际价格下调幅度有多大?哪些关键因素影响降幅?如何能进一步扩大此类药品的可及性?近期,业内专家进行了深入分析。抗癌药价格到底能降多少?从今年5月1日起,进口抗癌药品关税降至零,原16%增值税可选择按3%简易纳税征收。有部分患者和媒体甚至解读为,“‘零关税’和增值税减按3%征收,相当

抗癌药迎来严格“降价令” 江西、海南设最后调价时限

在国家医保局的大力推动下,抗癌药价格下降已初见成效。近日,海南和江西两省药品招标采购中心分别发布抗癌药集中调价公告,令大量国产和进口抗癌药迎来最新一轮“降价潮”。逾期不降价就不采购8月6日,江西省医药采购服务平台发布《关于开展进口药品和抗癌药品价格申报的通知》(以下简称《通知》),要求已纳入江西省网上采购平台的且属于降低关税和增值税范围内的进口药和抗癌药品,按照降价金额不少于降税金额的原则,

Nature:要当心!科研机构的癌细胞系竟在偷偷“进化”,抗癌药物研究变数陡增

本周的《自然》杂志刊登了来自Broad研究所的最新科研成果。研究者们对比了来自两个数据库的106个癌细胞系的外显子测序数据,发现同一细胞系之间竟然五分之一的基因序列差异!进一步分析了单一乳腺癌细胞系的27个细胞株,研究者发现同样存在高水平的遗传多样性,测试的321种抗癌化合物中,有75%虽然能对特定细胞株产生抗癌活性,但是在其他细胞株中完全没用!

抗癌药零关税满百天:多部门力促降价 国产药创新仿制齐头并进

自今年5月1日起,中国实施抗癌药等药品“零关税”已满百日。三个多月来,多地多部门多措并举,通过医保准入谈判、省级抗癌药专项集中采购、加快境外新药审批流程、纳入医保等举措,力促民众买得到、用得起“救命药”。多措并举 让“救命药”买得到、用得起一段时间以来,抗癌药的话题成为民众关注的焦点。在抗癌药零关税政策实施满3个月后,国家卫生健康委、国家医保局、国家药监局等相关部门密集发声,介绍相关政策措施

专家:抗癌药税改政策对终端价格将产生多大影响

抗癌药品价格是社会普遍关心的问题。国务院有关部门规定,从今年5月1日起,进口抗癌药品关税降至零,原16%增值税可选择按3%简易纳税征收。调降抗癌药品的关税与增值税,表明本届政府重视民生问题、切实提高人民获得感和幸福感的决心。在中美贸易摩擦不断升级的国际大背景下,彰显了党和国家“一切以人民为中心”的施政理念。

断供18个月的消化道癌药恢复生产 但廉价救命药短缺问题仍未解决

已经在市场上消失了近18个月的短缺药注射用丝裂霉素,终于在近日恢复生产。8月9日,瀚晖制药正式对外宣布,注射用丝裂霉素已于本月检验合格,并正式发运、独家上市。首批生产的2000瓶注射用丝裂霉素,将捐赠送往急需的国内医疗机构,后续扩产药品则会在8月下旬正式上市供应。公开资料显示,注射用丝裂霉素是目前各国常用的抗肿瘤药,对消化道癌症的治疗效果显着,也是青光眼手术必备药物。据了解,青光眼手术要在眼部做一